Canaccord Genuity Rates Bioventus (BVS) buy, $15 Price Target

Canaccord Genuity reaffirms its buy rating on Bioventus Inc. with a $15 price target, a 70.65% upside from the current price.

By EarningsIQ Research Desk · Published Jun 17, 2026, 2:02 AM EDT · Updated Jun 23, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity rated Bioventus Inc. ($BVS) "buy" with a $15 price target on June 16, 2026.

Since the rating, $BVS is up 6.5% after 1 week, up 42.5% after 1 month and up 52.5% to date (from the $8.72 close on Jun 16, 2026).

BVS Bioventus Inc.

$13.30 +84.47% year to date

Daily close · Oct 16, 2026

Key Points

On June 16, 2026, Canaccord Genuity reaffirmed its buy rating on Bioventus Inc. with a $15 price target.
Canaccord Genuity's $15 price target implies 70.65% upside from Bioventus Inc.'s ($BVS) current $8.79 share price.
Bioventus Inc. trades at $8.60 with a market cap of approximately $590.8 million and a forward P/E of 9.62.
Insiders recently bought shares, and analysts maintain a positive outlook with a consensus target of $14.80.

Get $BVS trade alerts by text

We text you when insiders, Congress or big funds trade $BVS. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Bioventus Inc. alert may contain errors. Disclosures

On June 16, 2026, Canaccord Genuity reiterated its buy rating on Bioventus Inc. (NasdaqGS: BVS), maintaining a price target of $15. This comes as Bioventus shares recently traded at $8.60.

Bioventus Inc. Stock Down 31.9%

Shares of Bioventus Inc. are trading around $8.60. The company has a market capitalization of approximately $590.8 million. It holds a P/E ratio of 21.27 and a forward P/E of 9.62, with a beta of 0.669. The stock's 52-week range has seen lows of $5.81 and highs of $11.25. Bioventus also has a 50-day moving average of $9.63 and a 200-day moving average of $8.17.

12-month forecast

$BVS price target

Bioventus Inc. daily closes and this analyst's $15 target. Not advice.

Recent Earnings

Bioventus reported revenues of $576.3 million, marking a growth of 6.6%. The company has a net margin of 4.94% and a return on equity of 16.46%. Its next earnings report is expected on August 4, 2026.

Insider Buying and Selling at Bioventus Inc.

Recent insider activity at Bioventus shows several insiders, including Philip Cowdy and Mary Kay Ladone, purchasing 25,146 shares each on June 3, 2026. Other insiders, such as Pat Beyer and William Hawkins, also bought shares on the same date.

Analysts Set New Price Targets

On June 16, 2026, Canaccord Genuity maintained its buy rating for Bioventus with a $15 price target. Barrington Research also maintained a buy rating with a $14 target on May 22, 2026. The consensus among analysts is a buy rating, with a mean target price of $14.80 based on five analyst opinions.

Other Institutional Activity in Bioventus Inc.

Among Bioventus' institutional investors, Nantahala Capital Management increased its position by 75,000 shares, bringing its total to 6,122,403 shares worth about $55.9 million. Royce & Associates significantly boosted its stake by 290,000 shares, now holding 1,541,282 shares valued at approximately $14.1 million. Meanwhile, BlackRock added 9,357 shares to reach a total of 3,133,541 shares, valued at $28.6 million.

About Bioventus Inc.

Bioventus Inc., based in Durham, North Carolina, is a medical device company that focuses on treatments for pain and musculoskeletal therapies. The company offers a range of products, including pain management injections and devices for peripheral nerve stimulation and bone resection. It also provides minimally invasive fracture treatments and rehabilitation products. Bioventus was founded in 2011 and currently employs about 940 people.

Bottom Line

Canaccord Genuity's reaffirmation of its buy rating on Bioventus Inc., along with a $15 price target, reflects confidence in the company's growth prospects. Investors often track such analyst opinions as they can influence market sentiment. It's important to remember that these ratings are based on past performance and available data, not future predictions.